Page last updated: 2024-12-05

sulfisomidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfisomidine is a sulfonamide antibiotic that was first synthesized in the 1950s. It acts by inhibiting the synthesis of dihydrofolic acid, a key coenzyme in bacterial metabolism. Sulfisomidine was widely used in the treatment of urinary tract infections, but its use has declined due to the emergence of resistant bacteria and the availability of newer antibiotics. It is still used in some countries, particularly for the treatment of certain types of bacterial infections in livestock. Sulfisomidine is often studied in the context of its potential for use in treating other types of infections, such as those caused by parasitic organisms. Its unique chemical structure and its ability to penetrate the blood-brain barrier make it a promising candidate for the development of new drugs. However, further research is needed to assess its safety and efficacy in humans.'

Sulfisomidine: A sulfanilamide antibacterial agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfisomidine : A sulfonamide consisting of pyrimidine having methyl substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5343
CHEMBL ID485696
CHEBI ID32166
SCHEMBL ID34791
MeSH IDM0020778

Synonyms (106)

Synonym
benzenesulfonamide, 4-amino-n-(2,6-dimethyl-4-pyrimidinyl)-
sulfaisodimidine
sulfadimetine
sulfisomidin
sulfamethin
mefenal
4-amino-n-(2,6-dimethylpyrimidin-4-yl)benzenesulfonamide
n(1)-(2,6-dimethyl-4-pyrimidinyl)sulfanilamide
515-64-0
sulfisomidine
D01526
sulfisomidine (jan)
sulfisomidine (tn)
NCGC00164492-01
n(sup 1)-(2,6-dimethyl-4-pyrimidinyl)sulfanilamide
2,4-dimethyl-6-sulfanilamidopyrimidine
erycon
6-sulfanilamido-2,4-dimethylpyrimidine
elkosil
elcosine
6-(p-aminobenzenesulfonamido)-2,4-dimethylpyrimidine
sulfisomidina [inn-spanish]
sulfanilamide, n(sup 1)-(2,6-dimethyl-4-pyrimidinyl)-
brn 0261305
6-(p-aminobenzenesulfonyl)amino-2,4-dimethylpyrimidine
4-sulfanilamido-2,6-dimethylpyrimidine
6-(4-aminobenzenesulfonamido)-2,4-dimethylpyrimidine
aristogyn
ai3-50168
sulfaisomidine
4-sulfa-2,6-dimethylpyrimidine
sulfisomidinum [inn-latin]
sulfaisodimerazine
einecs 208-204-3
elkosin
elkosine
aristamid
isosulf
sulfisomidine [jan]
(p-aminobenzolsulfonyl)-4-amino-2,6-dimethylpyrimidin [german]
n1-(2,6-dimethyl-4-pyrimidinyl)sulfanilamide
sulfasomidine
2,6-dimethyl-4-sulfanilamidopyrimidine
domian
sulphasomidine
solfisomidina [dcit]
sulfaisodimidinum
OPREA1_339670
F1716-0354
yzmckzraolzxaz-uhfffaoysa-
inchi=1/c12h14n4o2s/c1-8-7-12(15-9(2)14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7h,13h2,1-2h3,(h,14,15,16)
(p-aminobenzolsulfonyl)-4-amino-2,6-dimethylpyrimidine
(p-aminobenzolsulfonyl)-4-amino-2,6-dimethylpyrimidin
solfisomidina
CHEBI:32166 ,
S0362
CHEMBL485696
AKOS000119092
NCGC00186655-01
4-amino-n-(2,6-dimethylpyrimidin-4-yl)benzene-1-sulfonamide
dtxsid1046390 ,
dtxcid9026390
cas-515-64-0
tox21_112130
MLS004773916
smr001346487
sulfisomidinum
sulfisomidina
w03l3odk6e ,
unii-w03l3odk6e
5-25-10-00216 (beilstein handbook reference)
sulfisomidine [inn:ban:jan]
FT-0632265
S5291
SCHEMBL34791
tox21_112130_1
NCGC00164492-02
sulfisomidine [ep impurity]
sulfisomidine [who-dd]
sulfisomidine [mart.]
sulfisomidine [mi]
sulfisomidine [inn]
YZMCKZRAOLZXAZ-UHFFFAOYSA-N
aristamide
elcosin
domain
CS-7658
STL481971
mfcd00010567
sr-01000940235
SR-01000940235-2
sulfisomidin, vetranal(tm), analytical standard
HY-B1784
benzenesulfonamide, 4-amino-n-(2,6-dimethyl-4-pyrimidinyl)-(9ci)
DB13283
sulfisomidine 100 microg/ml in acetonitrile
AS-10637
Q6577315
A12593
EN300-19077
CCG-267227
SB58524
NCGC00164492-03
bdbm50548727
sulfamethin;sulfaisodimidine
Z104472628

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The suction blister technique was used for pharmacokinetic studies with sulfonamides and trimethoprim."( Pharmacokinetic studies of antibacterial agents using the suction blister method.
Bredesen, JE; Bruun, JN; Kierulf, P; Lunde, PK, 1990
)
0.28
" The pregnant uterus could not be recognised as an extra compartment, either in distribution volume nor in the pharmacokinetic model."( Influence of gestation on the pharmacokinetics of four sulphonamides in goats.
Van Deurzen, JM; Van Duin, CT; Van Gogh, H; Van Miert, AS, 1990
)
0.28
"The pharmacokinetic properties of three sulphonamides were determined in ruminant and preruminant kids after oral and intravenous administration."( Pharmacokinetics of three sulphonamides in ruminant and preruminant kids.
van Deurzen, EJ; van Duin, CT; van Gogh, H; van Miert, AS; Watson, AD, 1987
)
0.27

Bioavailability

ExcerptReferenceRelevance
"After intravenous and oral application of 25 mg 6-(sulfanilamido)-2,4-dimethyl-pyrimidine (sulfasomidin)/kg body-weight to 29 newborns, 8 infants and 9 older children the completeness and rate of absorption were determined."( [Enteral absorption of sulfasomidine depending on age (author's transl)].
Gladtke, E; Heimann, G; Mensah-Kordieh, J; Roth, B, 1978
)
0.26
"The influence of food intake on the bioavailability of a frequently used short-acting sulfonamide, sulfaisomidine (Elkosin), has been examined in eight healthy volunteers."( On the influence of concomitant food intake on sulfonamide bioavailability.
Danielson, K; Melander, A; Rerup, C; Wåhlin, E, 1976
)
0.26
" Of the three drugs tested, SDX might be the most satisfactory for therapeutic use in preruminant animals, because it has good bioavailability after oral administration and long t1/2(el)."( Pharmacokinetics of three sulphonamides in ruminant and preruminant kids.
van Deurzen, EJ; van Duin, CT; van Gogh, H; van Miert, AS; Watson, AD, 1987
)
0.27
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"The effect of model polymer coating films of vinyl acetate, containing oxybenzone as a UV absorber, on the coloration and photolytic degradation of simple sulfisomidine tablets was examined to attempt stabilization of photosensitive solid dosage forms."( Stabilization of sulfisomidine tablets by use of film coating containing UV absorber: Protection of coloration and photolytic degradation from exaggerated light.
Inouye, H; Matsuda, Y; Nakanishi, R, 1978
)
0.8
" This suggests that the use of standardized size and interval of sulfaisodimidine dosage can be recommended."( On the influence of concomitant food intake on sulfonamide bioavailability.
Danielson, K; Melander, A; Rerup, C; Wåhlin, E, 1976
)
0.26
" Thus, the two regimens seemed to be equally efficient, and the risk of therapy failure due to low blood concentrations of sulfaisodimidine should not be greater when the drug is given in a dosage of 2 g twice daily than when it is administered in the conventional way."( Therapeutic equivalence of sulfaisodimidine 2 g twice daily and 1 g four times daily in lower urinary tract infections.
Bitzén, PO; Melander, A; Olsson, S, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency43.64860.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency24.34140.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency12.32950.000221.22318,912.5098AID743054; AID743063
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency13.58730.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.48660.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency7.66400.000214.376460.0339AID720691; AID720692
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein argonaute-2Homo sapiens (human)Kd4.30004.30004.30004.3000AID1682438
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (24)

Processvia Protein(s)Taxonomy
translationProtein argonaute-2Homo sapiens (human)
translational initiationProtein argonaute-2Homo sapiens (human)
post-embryonic developmentProtein argonaute-2Homo sapiens (human)
RNA secondary structure unwindingProtein argonaute-2Homo sapiens (human)
miRNA metabolic processProtein argonaute-2Homo sapiens (human)
siRNA processingProtein argonaute-2Homo sapiens (human)
regulatory ncRNA-mediated gene silencingProtein argonaute-2Homo sapiens (human)
pre-miRNA processingProtein argonaute-2Homo sapiens (human)
P-body assemblyProtein argonaute-2Homo sapiens (human)
regulatory ncRNA-mediated post-transcriptional gene silencingProtein argonaute-2Homo sapiens (human)
miRNA processingProtein argonaute-2Homo sapiens (human)
miRNA-mediated gene silencing by inhibition of translationProtein argonaute-2Homo sapiens (human)
miRNA-mediated gene silencing by mRNA destabilizationProtein argonaute-2Homo sapiens (human)
negative regulation of amyloid precursor protein biosynthetic processProtein argonaute-2Homo sapiens (human)
positive regulation of translationProtein argonaute-2Homo sapiens (human)
positive regulation of angiogenesisProtein argonaute-2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIProtein argonaute-2Homo sapiens (human)
negative regulation of translational initiationProtein argonaute-2Homo sapiens (human)
positive regulation of nuclear-transcribed mRNA poly(A) tail shorteningProtein argonaute-2Homo sapiens (human)
RISC complex assemblyProtein argonaute-2Homo sapiens (human)
regulation of synapse maturationProtein argonaute-2Homo sapiens (human)
siRNA-mediated gene silencing by mRNA destabilizationProtein argonaute-2Homo sapiens (human)
positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decayProtein argonaute-2Homo sapiens (human)
positive regulation of trophoblast cell migrationProtein argonaute-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (16)

Processvia Protein(s)Taxonomy
siRNA bindingProtein argonaute-2Homo sapiens (human)
RNA 7-methylguanosine cap bindingProtein argonaute-2Homo sapiens (human)
RNA polymerase II complex bindingProtein argonaute-2Homo sapiens (human)
core promoter sequence-specific DNA bindingProtein argonaute-2Homo sapiens (human)
RNA bindingProtein argonaute-2Homo sapiens (human)
double-stranded RNA bindingProtein argonaute-2Homo sapiens (human)
single-stranded RNA bindingProtein argonaute-2Homo sapiens (human)
translation initiation factor activityProtein argonaute-2Homo sapiens (human)
RNA endonuclease activityProtein argonaute-2Homo sapiens (human)
protein bindingProtein argonaute-2Homo sapiens (human)
siRNA bindingProtein argonaute-2Homo sapiens (human)
miRNA bindingProtein argonaute-2Homo sapiens (human)
mRNA 3'-UTR AU-rich region bindingProtein argonaute-2Homo sapiens (human)
metal ion bindingProtein argonaute-2Homo sapiens (human)
endoribonuclease activity, cleaving siRNA-paired mRNAProtein argonaute-2Homo sapiens (human)
endoribonuclease activity, cleaving miRNA-paired mRNAProtein argonaute-2Homo sapiens (human)
mRNA cap bindingProtein argonaute-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
postsynapseProtein argonaute-2Homo sapiens (human)
glutamatergic synapseProtein argonaute-2Homo sapiens (human)
P-bodyProtein argonaute-2Homo sapiens (human)
nucleusProtein argonaute-2Homo sapiens (human)
nucleoplasmProtein argonaute-2Homo sapiens (human)
cytoplasmProtein argonaute-2Homo sapiens (human)
cytosolProtein argonaute-2Homo sapiens (human)
membraneProtein argonaute-2Homo sapiens (human)
dendriteProtein argonaute-2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProtein argonaute-2Homo sapiens (human)
extracellular exosomeProtein argonaute-2Homo sapiens (human)
RISC-loading complexProtein argonaute-2Homo sapiens (human)
RISC complexProtein argonaute-2Homo sapiens (human)
nucleusProtein argonaute-2Homo sapiens (human)
cytoplasmProtein argonaute-2Homo sapiens (human)
cytoplasmic ribonucleoprotein granuleProtein argonaute-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (62)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1682437Binding affinity to human Argonaut protein 2 PAZ domain assessed as association constant by using isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID1682441Inhibition of RNAi in human Hela cells expressing Renilla/firefly luciferase genes and siRNA assessed as siRNA-mediated gene silencing activity at 100 to 500 nM by dual luciferase assay relative to control2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1682440Binding affinity to human Argonaut protein 2 PAZ domain assessed as change in entropy by isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1682439Binding affinity to human Argonaut protein 2 PAZ domain assessed as change in enthalpy by isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID599143Lipophilicity, log P of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1682438Binding affinity to human Argonaut protein 2 PAZ domain assessed as dissociation constant by using isothermal titration microcalorimetry2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID1682442Inhibition of RNAi in human Hela cells expressing Renilla/firefly luciferase genes and siRNA assessed as siRNA-mediated gene silencing activity at 500 nM by dual luciferase assay relative to control2020Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24
Sulfonamide antibiotics inhibit RNAi by binding to human Argonaute protein 2 PAZ.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID599144Intrinsic solubility, log 1/S0 of the compound2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Computational aqueous solubility prediction for drug-like compounds in congeneric series.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (157)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990136 (86.62)18.7374
1990's5 (3.18)18.2507
2000's3 (1.91)29.6817
2010's5 (3.18)24.3611
2020's8 (5.10)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.96 (24.57)
Research Supply Index5.13 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (1.82%)5.53%
Reviews5 (3.03%)6.00%
Case Studies2 (1.21%)4.05%
Observational0 (0.00%)0.25%
Other155 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]